title: The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome.
abstract: BACKGROUND
  Drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms (DIHS/DRESS) and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) represent contrasting poles of severe drug eruptions, and sequential reactivations of several herpesviruses have exclusively been demonstrated in the former. No previous studies, however, were extended beyond the acute stage. We sought to investigate whether herpesvirus reactivations could also be observed in SJS/TEN and beyond the acute stage of both diseases.
  
  
  METHODS
  Patients with SJS (n = 16), SJS/TEN overlap (n = 2), TEN (n = 10), and DIHS/DRESS (n = 34) were enrolled. We performed a retrospective analysis of Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and cytomegalovirus (CMV) DNA loads sequentially determined by real-time polymerase chain reaction during a 2-year period after onset.
  
  
  RESULTS
  Persistently increased EBV loads were detected in SJS during the acute stage and long after resolution, but not in others. In contrast, high HHV-6 loads were exclusively detected in DIHS/DRESS during the acute stage. The dynamics of herpesvirus reactivation varied in DIHS/DRESS according to the use of systemic corticosteroids: While EBV loads were higher in patients not receiving systemic corticosteroids, CMV and HHV-6 loads were higher in those receiving them.
  
  
  CONCLUSIONS
  Distinct patterns of herpesvirus reactivation according to the pathological phenotype and to the use of systemic corticosteroids were observed during the acute stage and follow-up period, which may contribute, at least in part, to the difference in the clinical manifestations and long-term outcomes. Systemic corticosteroids during the acute stage may improve the outcomes in DIHS/DRESS.
authors.affiliation: Department of Dermatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ishida
authors.forename: Y
authors.initials: Y
authors.lastname: Kano
authors.forename: Y
authors.initials: Y
authors.lastname: Mizukawa
authors.forename: T
authors.initials: T
authors.lastname: Shiohara
mesh_terms: D000328:Adult; D000368:Aged; D004279:DNA, Viral; D003875:Drug Eruptions / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006564:Herpesviridae / Q000187:drug effects / Q000235:genetics*; D006566:Herpesviridae Infections / Q000150:complications* / Q000821:virology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010641:Phenotype; D012189:Retrospective Studies; D013262:Stevens-Johnson Syndrome / Q000150:complications / Q000175:diagnosis; D013997:Time Factors; D019562:Viral Load; D014775:Virus Activation / Q000187:drug effects
chemical_list: D004279:DNA, Viral; D007166:Immunosuppressive Agents
keywords: Epstein-Barr virus; Stevens-Johnson syndrome/toxic epidermal necrolysis; cytomegalovirus; drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms; human herpesvirus 6
references.citation: Blood. 2006 Feb 1;107(3):862-9
references.pmid: 16234359
references.citation: J Exp Med. 1995 Dec 1;182(6):1703-15
references.pmid: 7500015
references.citation: J Am Acad Dermatol. 2005 Feb;52(2):312-5
references.pmid: 15692479
references.citation: J Eur Acad Dermatol Venereol. 2008 Sep;22(9):1044-9
references.pmid: 18627428
references.citation: Pediatrics. 2007 Apr;119(4):e1002-5
references.pmid: 17353300
references.citation: Clin Exp Dermatol. 2010 Dec;35(8):863-8
references.pmid: 20456395
references.citation: Arch Dermatol. 2009 Jan;145(1):63-6
references.pmid: 19153345
references.citation: Autoimmun Rev. 2009 May;8(6):488-94
references.pmid: 19239928
references.citation: Arch Dermatol. 2009 Sep;145(9):1030-6
references.pmid: 19770444
references.citation: Arch Dermatol. 2009 Jan;145(1):67-72
references.pmid: 19153346
references.citation: Allergy. 2014 Jun;69(6):798-805
references.pmid: 24749495
references.citation: Expert Rev Clin Immunol. 2011 Nov;7(6):803-13; quiz 814-5
references.pmid: 22014021
references.citation: Diagn Pathol. 2013 Aug 06;8:134
references.pmid: 23919759
references.citation: Allergy. 2007 May;62(5):527-31
references.pmid: 17313402
references.citation: J Am Acad Dermatol. 2007 Feb;56(2):181-200
references.pmid: 17224365
references.citation: Arch Dermatol. 1998 Sep;134(9):1108-12
references.pmid: 9762023
references.citation: J Am Acad Dermatol. 2013 May;68(5):721-8
references.pmid: 23182063
references.citation: Br J Dermatol. 2007 May;156(5):1083-4
references.pmid: 17381452
references.citation: N Engl J Med. 1994 Nov 10;331(19):1272-85
references.pmid: 7794310
references.citation: Arch Dermatol. 1993 Jan;129(1):92-6
references.pmid: 8420497
references.citation: Eur J Dermatol. 2012 Jan-Feb;22(1):144-5
references.pmid: 22064249
references.citation: J Am Acad Dermatol. 1996 Nov;35(5 Pt 1):757-60
references.pmid: 8912572
references.citation: Drug Saf. 2002;25(13):965-72
references.pmid: 12381216
references.citation: J Dermatol. 2006 Sep;33(9):616-22
references.pmid: 16958806
references.citation: Clin Rev Allergy Immunol. 2007 Oct;33(1-2):124-33
references.pmid: 18094951
references.citation: Ocul Surf. 2008 Apr;6(2):87-95
references.pmid: 18418506
references.citation: Oncogene. 2003 Aug 11;22(33):5108-21
references.pmid: 12910248
references.citation: Blood. 2009 Sep 10;114(11):2244-53
references.pmid: 19617574
references.citation: Arch Dermatol. 1995 Nov;131(11):1268-72
references.pmid: 7503570